Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
M.D. Anderson Cancer Center
University of Alabama at Birmingham
National Cancer Institute (NCI)
Qilu Pharmaceutical Co., Ltd.
City of Hope Medical Center
National Cancer Institute (NCI)
AbbVie
Genmab
AstraZeneca
Neonc Technologies, Inc.
Imunon
Wake Forest University Health Sciences
Imunon
Imunon
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
AbbVie
AstraZeneca
AstraZeneca
Jiangsu Cancer Institute & Hospital
Ohio State University Comprehensive Cancer Center
AstraZeneca
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
NRG Oncology
Eli Lilly and Company
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
OHSU Knight Cancer Institute
TORL Biotherapeutics, LLC
National Institutes of Health Clinical Center (CC)
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
AstraZeneca
GlaxoSmithKline
Hospices Civils de Lyon
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Zhejiang Cancer Hospital
University Health Network, Toronto
National Cancer Institute (NCI)